You're using an outdated browser. Please upgrade to a modern browser for the best experience.
DNA-Modifying Enzymes in Myelodysplastic Syndromes: Comparison
View Latest Version
Please note this is a comparison between Version 3 by Rita Xu and Version 2 by Rita Xu.

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders with maturation and differentiation defects, exhibiting morphological dysplasia in one or more hematopoietic cell lineages, and are characterized by increased risk for progression into acute myelogenous leukemia (AML). Among their multifactorial pathogenesis, age-related epigenetic instability and the error-rate DNA methylation maintenance have been recognized as critical factors for both, the initial steps of their pathogenesis and disease progression. DNA-modifying enzymes, commonly mutated in MDS, play a crucial role in this epigenetic drift.

  • myelodysplastic syndromes
  • acute myeloid leukemia
  • aberrant DNA methylation
  • pathogenesis
  • epigenetics
  • small non-coding RNAs

1. Introduction

Among theAmong the complex and multifactorial pathophysiology of MDS, apart from various somatic mutations, occurring at genetic loci with essential role in the growth, development and differentiation of hematopoietic cells, hypermethylation of several genetic loci plays a dominant role in all phases of the disease, from the generation of a clonal cell population until disease evolution to AML complex and multifactorial pathophysiology of MDS, hypermethylation of several genetic loci plays a dominant role in all phases of the disease, from the early steps of generation of a clonal cell population until disease evolution to AML. Since MDS is heterogeneous disease, identification of easily recognized prognostic factors is of tremendous importance, and to this point the international prognostic scoring system (IPSS) or its revised form (IPSS-R) represents standard and useful tools for the assessment of risk categorization and prognosis, taking into account cytogenetics, the number and severity of cytopenias and bone marrow blasts percentage [1][2][3].
TheIn MDS commonly mutated genes, which are implicated in epigenetics, include DNA methyltransferases (DNMTs) DNMT1 and mainly DNMT3A, the family of methyl-cytosine dioxygenases TET1-3 and the isocitrate dehydrogenases IDH1-2, contributing to the generation of aberrant methylation/demethylation genomic imprints dominant role in the initial pathogenesis of MDS has various somatic mutations, occurring at genetic loci with essential role in growth, development and differentiation of hematopoietic cells, as well as in epigenetic alterations, since MDS patients display abnormal hypermethylation patterns across many genomic regions [4][5][6][7]. Commonly mutated genetic loci in MDS which are implicated in epigenetics include DNA methyltransferases DNMT1 and mainly DNMT3A, the family of methyl-cytosine dioxygenases TET1-3 and the isocitrate dehydrogenases IDH1-2, contributing to the generation of aberrant methylation/demethylation genomic imprints [8][9][10]. DNNMTs catalyze the reaction of cytosine methylation on DNA CpG dinucleotides, while the family of TET enzymes converts 5-methylcytocine (5mC) to 5-hydroxy-methylcytocine (5hmC) and other downstream oxidative products, which leads to DNA demethylation in daughter cells due to the inability of DNMT1 to recognize the modification from 5mC to 5hmC [117]. Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutated IDH1 catalyzes the synthesis of 2-hydroxyglutarate, which inhibits alpha-ketoglutarate dependent enzymes such as the TETs and the histone demethylases, which indirectly leads to an elevation in 5mC levels within genome and a hypermethylated phenotype [128]. These enzyme families have been associated with harmful pathogenetic background, often acquired with advancing age and they are well known to be involved in disorders, such as MDS and various cancers of epithelial origin. Currently, the enhancement or silencing of other gene loci encoding for non-coding RNAs (ncRNAs) have also highlighted their role in the onset and course of MDS, as well as in the response to various treatment approaches, applied to these patients and in the risk to pathophysiology of AML progression [13] Differential expression of long ncRNAs appears as potential biomarkers for disease progression [14][15]. Moreover, deviating expression profiles of other ncRNAs, such as miRNAs (micro-RNAs), are detected in plasma or in bone marrow mononuclear cells during transformation of MDS to AML or in treatment intervals with hypomethylating agents [16][17][18].
HypomethylatingHypomethylating agents (HMAs), mainly azacytidine (AZA) and decitabine (DAC), used in clinical practice, are primarily considered inhibitors of DNMTs, mostly of DNMT1 agents (HMAs), mainly azacytidine (AZA) and decitabine (DAC), used in clinical practice, are primarily considered inhibitors of DNA methyltransferases (DNMTs), mostly of DNMT1 [199]. AZAAZA and DAC are both, chemical nucleoside analogs of cytidine with identical ring structure, thus acting also as antimetabolites inside the rapidly proliferating immature clonal cells, besides their inhibitory activity on DNMTs. These agents, after incorporation into DNA and/or RNA of highly proliferating cells, mainly induce DNMT1 depletion and global DNA hypomethylation. However, their function is not equivalent, and distinctly different effects have been reported for their specific mode of action, with AZA exhibiting a greater effect on the reduction of cell viability and total protein synthesis and on restoration of onco-suppressing gene expression and DAC are both chemical nucleoside analogs of cytidine with identical ring structure, thus acting also as antimetabolites inside the rapidly proliferating immature clonal cells. These agents, after incorporation into DNA and/or RNA of highly proliferating cells, mainly induce DNMT1 depletion and global DNA hypomethylation. However, their function is not equivalent and distinctly different effects have been reported for their specific mode of action, with AZA having a greater effect on reduction of cell viability and total protein synthesis and also, restoration of onco-suppressing gene’s expression [2010].
EffortsEfforts to understand in depth step by step the pathogenetic mechanisms of MDS, although challenging, have not resulted in much therapeutic progress in recent years. For almost the last two decades HMAs remain the mainstay of treatment for non-transplant eligible patients, with higher-risk MDS (HR-MDS) and AML, despite the fact that only 30–50% of them may achieve a substantial and durable response to understand in depth the underlying pathogenetic mechanisms of MDS have not attained much therapeutic progress in recent years. HMAs remain for almost two decades the mainstay of treatment for non-transplant eligible patients with higher-risk MDS (HR-MDS) and AML, despite the fact that only 30–50% of them may achieve a substantial response [2111][2212] and is also. Although HMAs are in use for long time, an association of demethylating effect on specific DNA hypermethylated loci with particular clinical outcomes and patterns of response, remains yet to be shown, while their broader mode of action on gene expression regulation is still unclear. According to current clinical experience, median overall survival with HMA monotherapy is about two years for HR-MDS patients used as bridging treatment for several patients, candidates for allogeneic stem cell transplantation (Allo-SCT). Despite the long-term use of HMAs, an association of demethylating effect on specific DNA hypermethylated loci with particular clinical patterns of response, remains yet to be shown, while their broader mode of action in gene expression regulation is still unclear. According to the existing clinical experience, median overall survival with HMA monotherapy is ∼18–20 months for HR-MDS patients [2313] andand less than a year for those with AML less than a year for those with AML [2111]. This observation implies that additional mechanisms, beyond specific demethylation genomic events are developed, ascribing to clonal cells a biologically more aggressive/leukemic phenotype. Thus, several classes of novel agents, promising to act synergistically with HMAs are emerging, to overcome the generation of resistance. RNA-based therapeutic agents are still in pre-clinical investigation and only a few of them have entered the clinical stage to evaluate their value in practice.This observation implies that additional mechanisms, beyond specific genomic hypo/demethylation events are developed, ascribing to clonal cells a biologically more aggressive/leukemic phenotype. Thus, several classes of novel agents, modifying different targets and promising to act synergistically with HMAs, are emerging, in an effort to overcome the generation of resistance. RNA-based therapeutic agents are still in pre-clinical investigation and only a few of them have entered the clinical stage to evaluate their value in practice.

2. The Course of Aberrant DNA Methylation Patterns in MDS

DNA methylation is an essential epigenetic mechanism, playing very important role in the regulation of gametogenesis and zygote development in mammals (orchestrating the rounds of erasing and re-methylating of maternal and paternal derived chromosomes), imprinting and tissue-specific gene’s expression, and preservation of DNA hypermethylation as a suppressing mechanism for the locomotion of repetitive DNA elements [2414][2515][2616]. Herein, enzymes responsible for epigenetic gene reprogramming are considered as delicate sensors of environmental signaling leading to cell responses and differential gene expression profiles. In particular, the epigenetic mark created by a methyl group covalent transfer, derived from the S-adenosyl methionine (SAM), to the 5′C position of a cytosine (C) either in scattered CpG dinucleotides across DNA sequences or in CpG islands, is catalyzed by DNMTs. By a rough classification DNMT1 is considered as the maintenance DNMT, which targets the hemi-methylated double stranded (ds)DNA to preserve the DNA methylation patterns post DNA replication and DNMT3A/DNMT3B as the de novo methylation enzymes, reacting with hemi-methylated and unmethylated dsDNA [2717][2818]. Contrary to DNMT1, responsible for the inherited DNA methylation, DNMT3A and DNMT3B are normally expressed and act during embryonic development or gametogenesis, independently from DNA replication. These enzymes share identical enzymatic centers at carboxyl-ends and different sequence patterns across N-ends that serve for communication with other molecules and for recognition and binding to DNA [2919]. DNA recognition by DNMT3A and DNMT3B, apart from the N-terminal PWWP domain (‘Pro-Trp-Trp-Pro’ core amino acid sequence) by which bind to DNA, depends also on flanking sequences neighboring CpG targets. DNMT3B shows a significant preference for CpG methylation in a TACG (G/A) context [3020], while other research groups have predicted that DNMT3A and DNMT3B preferentially methylate some representative sequences, more frequently found in naturally over-methylated genes [3121][3222] or that DNMTs in general, favor recruitment at DNA repair sites [3323]. Furthermore, it has been reported that methylation of the Caspase-8 (CASP8) gene promoter in glioma cells is governed by both DNMT1 and DNMT3A, indicating a potential collaboration and concerted action of DNMTs [3424]. Specific recruitment assisted by transcription factors or chromatin remodeling complexes is another context supporting DNMTs’ symmetrical function on DNA methylation [3525]. However, there are still some interesting questions, such as the broader DNA architecture and/or epigenetic landscape that allows DNMTs to bind to CpG target sites in preferable or cognate sites or whether the flanking sequence preferences adapt to specific biological targets of DNMTs. Within this frame of action, crosstalk of DNMTs with non-coding RNA species as potential guides to specific sites for methylation across genome, remains an issue deserving further investigation. DNMT3A and DNMT3B are frequently associated with divergent de novo DNA methylation patterns and gene repression in many pathologies. A common observation is that Myelodysplastic Syndromes are developed under an aberrant epigenetic background [106]. Cell cycle regulators, apoptotic genes, and DNA repair genes are irregularly silenced through epigenetic modifications, promoting clonal dominance and expansion of abnormal hematopoietic stem cell, favoring gradual disease progression or in association with various other somatic mutations, the transformation to AML [3626]. Figure 1 illustrates phenotypic and functional cell alterations in hematopoietic stem cell (HSC) compartment of bone marrow, associated with HR-MDS that guide disease progression to AML. In MDS-derived secondary AML, mutations among the DNMTs and the TET family of genes contributing to demethylating genome pathways are frequently identified, suggesting that aberrant epigenetic programming plays a crucial role in MDS progression [106].
Ijms 23 16069 g001
Figure 1. Overview of cells’ aberrations in epigenome of higher-risk MDS patients within the hematopoietic stem cell (HSC) compartment of bone marrow. Impaired gene expression implicated in maturation and differentiation of pluripotent stem cells give rise to myeloid lineage-committed cells showing further phenotypical as well as functional changes. MDS patients of the higher-risk group present significantly expanded granulocytic-monocytic progenitor cells and HSC compartments, while the megakaryocytic–erythroid progenitor cell population is severely reduced. Cellular and molecular changes are in line with the observed cytopenias and emergence of aberrant blast cells in the bone marrow and peripheral blood of higher-risk MDS patients. Aberrant cells characterized by the generation of multiple copies per cell, are indicated by a solid red star. Obstructed pathways of myelopoiesis and erythropoiesis are indicated within a transparent rectangle.
Cytosine methylation in CpG dinucleotides is a critical epigenetic modification, although it can be reversible. DNA demethylation occurs via a stepwise oxidation of 5-methylcytosine that is catalyzed by the Ten-Eleven Translocation or methyl-cytosine dioxygenases (TET) enzymes. The first oxidation product in this process, 5-hydroxymethylcytosine (5hmC), has been shown to act as a unique epigenetic mark, which, in contrary to 5mC, is linked to transcriptional activation. 5hmC has been implicated in the activation of lineage-specific enhancers and in substantial cell processes [3727]. The oxidation pathway generates also several other intermediates (i.e., formylcytosine and carboxylcytosine), that have their own distinct biological functions [3828]. The 5hmC has a functional role in promoting gene expression during active demethylation, where conversion of 5mC to 5hmC by the TETs prevent the recognition of DNA sequences by repressive (Methyl-Binding) MBD-domain complexes and DNMT proteins that would typically be recruited to rich 5mC areas [3929]. The issue of cytosine epigenetic modifications across DNA CpG rich sequences apparently provides another layer of regulation, beyond the canonical genetic codes. Hypomethylating agents (HMAs) are mainly administered as treatment to HR-MDS patients with increased percentage of bone marrow blasts, carrying a high risk for AML development [4030]. Among the most widely administered MDS treatment approaches, AZA and DAC, are considered inhibitors of DNMT1, which is almost completely depleted after HMA exposure, whereas DNMT3A is significantly less sensitive and DNMT3B seems completely resistant to HMAs [199]. DAC is tri-phosphorylated and is incorporated into newly synthesized DNA as a substitute for cytosine (antimetabolite), which pairs with guanine assisted by DNA-polymerase, in contrast, AZA is converted to ribonucleoside triphosphate and is incorporated into RNA, leading to inhibition of protein synthesis [4131]. Investigation has shown that DNMT1 activity decreases faster than incorporation of HMAs into DNA [199][4232][4333] and DNMT1 depletion occurs even in the absence of DNA replication and cell division [4434][4535]. The DNMT1 depletion mechanism proposed, supporting these data, is that HMAs induce DNMT1 degradation in the nucleus via its rapid hyperphosphorylation by the protein kinase C delta (PKCd), followed by ubiquitination and finally leading to proteasomal degradation [199]. Although shared epigenetic mechanisms of action have been affiliated to both AZA and DAC, such as the DNMT1 depletion and global DNA hypomethylation, their function is not equivalent. Distinctive effects have been reported on many cellular responses, such as cell viability and gene expression [2010]. In proliferating cells, inactivation of DMNT1 after starting treatment with HMAs, results in a persistent hemi-methylated DNA status delivered to next generations of daughter cells. However, HMAs’ reversible activity towards the abnormal epigenetic stem cell profiles and reactivation of aberrantly silenced genes is moderate to low [4636]. Response to HMA therapy is not always easily predictable, since the required molecular genetic testing is not usually applied in routine clinical practice and most MDS patients who receive HMA therapy develop resistance to treatment over time and disease progression to AML [4737].

3. Non-Coding RNA Species Cooperate with DNA Modifying Enzymes

In addition to DNMTs, other epigenetic components, such as microRNAs (miRNAs) and small interfering RNAs (siRNAs) exhibit altered expression profiles in MDS patients, following treatment with HMAs and during disease progression, whereas long non-coding RNAs (lncRNAs) have been shown to direct the activity of epigenetic mechanisms and chromatin remodeling complexes in many genetic loci, influencing gene expression. DNA methylation spreading restrictions depending on RNA inhibition is a cooperative epigenetic phenomenon, and potentially represents a global way of inter-regulation between mechanisms, which are still considered distinct. So far there are few, but well-documented paradigms of interrelations between small non-coding RNA and proteins related to DNA or formation of DNA-ncRNA hybrids with regulatory functions. Current knowledge and future perspectives in nc-RNA interaction with DNA-modifying enzymes in MDS are well described in the recent work.

Under the enlightenment of these important but still restricted data, it is anticipated that nc-RNAs could potentially mediate the accurate targeting of CpG sites across the genome, offering guidance to DNMTs via sequence complementarity (between DNA and RNA) or alternatively, they could play the role of scaffolds, that recruit other DNA-modifying enzymes. Non-coding RNAs with secondary loops, such as the inter-nuclear transcribed pre-miRNA clusters and lncRNAs govern the structural principles for DNA–RNA–protein interactions. The above-mentioned speculations remain to be highlighted and elucidated in the near future.

References

  1. Malcovati, L.; Hellstrom-Lindberg, E.; Bowen, D.; Ades, L.; Cermak, J.; Del Canizo, C.; Della Porta, M.G.; Fenaux, P.; Gattermann, N.; Germing, U.; et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet. Blood 2013, 122, 2943–2964.
  2. Greenberg, P.; Cox, C.; LeBeau, M.M.; Fenaux, P.; Morel, P.; Sanz, G.; Sanz, M.; Vallespi, T.; Hamblin, T.; Oscier, D.; et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89, 2079–2088.
  3. Greenberg, P.L.; Tuechler, H.; Schanz, J.; Sanz, G.; Garcia-Manero, G.; Sole, F.; Bennett, J.M.; Bowen, D.; Fenaux, P.; Dreyfus, F.; et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120, 2454–2465.
  4. Figueroa, M.E.; Skrabanek, L.; Li, Y.; Jiemjit, A.; Fandy, T.E.; Paietta, E.; Fernandez, H.; Tallman, M.S.; Greally, J.M.; Carraway, H.; et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114, 3448–3458. Papaemmanuil, E.; Gerstung, M.; Malcovati, L.; Tauro, S.; Gundem, G.; van Loo, P.; Yoon, C.J.; Ellis, P.; Wedge, D.C.; Pellagatti, A.; et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122, 3616–3627.
  5. Maegawa, S.; Gough, S.M.; Watanabe-Okochi, N.; Lu, Y.; Zhang, N.; Castoro, R.J.; Estecio, M.R.; Jelinek, J.; Liang, S.; Kitamura, T.; et al. Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res. 2014, 24, 580–591. Haferlach, T.; Nagata, Y.; Grossmann, V.; Okuno, Y.; Bacher, U.; Nagae, G.; Schnittger, S.; Sanada, M.; Kon, A.; Alpermann, T.; et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28, 241–247.
  6. Jiang, Y.; Dunbar, A.; Gondek, L.P.; Mohan, S.; Rataul, M.; O’Keefe, C.; Sekeres, M.; Saunthararajah, Y.; Maciejewski, J.P. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113, 1315–1325. Heuser, M.; Yun, H.; Thol, F. Epigenetics in myelodysplastic syndromes. Semin. Cancer Biol. 2018, 51, 170–179.
  7. Zhao, X.; Yang, F.; Li, S.; Liu, M.; Ying, S.; Jia, X.; Wang, X. CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression. Br. J. Haematol. 2014, 165, 649–658. Madzo, J.; Vasanthakumar, A.; Godley, L.A. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Semin. Hematol. 2013, 50, 61–69.
  8. Papaemmanuil, E.; Gerstung, M.; Malcovati, L.; Tauro, S.; Gundem, G.; van Loo, P.; Yoon, C.J.; Ellis, P.; Wedge, D.C.; Pellagatti, A.; et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122, 3616–3627. Reitman, Z.J.; Jin, G.; Karoly, E.D.; Spasojevic, I.; Yang, J.; Kinzler, K.W.; He, Y.; Bigner, D.D.; Vogelstein, B.; Yan, H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. USA 2011, 108, 3270–3275.
  9. Haferlach, T.; Nagata, Y.; Grossmann, V.; Okuno, Y.; Bacher, U.; Nagae, G.; Schnittger, S.; Sanada, M.; Kon, A.; Alpermann, T.; et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28, 241–247. Ghoshal, K.; Datta, J.; Majumder, S.; Bai, S.; Kutay, H.; Motiwala, T.; Jacob, S.T. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 2005, 25, 4727–4741.
  10. Heuser, M.; Yun, H.; Thol, F. Epigenetics in myelodysplastic syndromes. Semin. Cancer Biol. 2018, 51, 170–179. Hollenbach, P.W.; Nguyen, A.N.; Brady, H.; Williams, M.; Ning, Y.; Richard, N.; Krushel, L.; Aukerman, S.L.; Heise, C.; MacBeth, K.J. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 2010, 5, e9001.
  11. Madzo, J.; Vasanthakumar, A.; Godley, L.A. Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Semin. Hematol. 2013, 50, 61–69. Dombret, H.; Seymour, J.F.; Butrym, A.; Wierzbowska, A.; Selleslag, D.; Jang, J.H.; Kumar, R.; Cavenagh, J.; Schuh, A.C.; Candoni, A.; et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015, 126, 291–299.
  12. Reitman, Z.J.; Jin, G.; Karoly, E.D.; Spasojevic, I.; Yang, J.; Kinzler, K.W.; He, Y.; Bigner, D.D.; Vogelstein, B.; Yan, H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. USA 2011, 108, 3270–3275. Fenaux, P.; Mufti, G.J.; Hellstrom-Lindberg, E.; Santini, V.; Finelli, C.; Giagounidis, A.; Schoch, R.; Gattermann, N.; Sanz, G.; List, A.; et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol. 2009, 10, 223–232.
  13. Bond, D.R.; Lee, H.J.; Enjeti, A.K. Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy. Cancers 2020, 12, 3128. Zeidan, A.M.; Stahl, M.; DeVeaux, M.; Giri, S.; Huntington, S.; Podoltsev, N.; Wang, R.; Ma, X.; Davidoff, A.J.; Gore, S.D. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: Are we using realistic estimates? Blood Cancer J. 2018, 8, 55.
  14. Zimta, A.A.; Tomuleasa, C.; Sahnoune, I.; Calin, G.A.; Berindan-Neagoe, I. Long Non-coding RNAs in Myeloid Malignancies. Front. Oncol. 2019, 9, 1048. Zeng, Y.; Chen, T. DNA Methylation Reprogramming during Mammalian Development. Genes 2019, 10, 257.
  15. Huang, H.H.; Chen, F.Y.; Chou, W.C.; Hou, H.A.; Ko, B.S.; Lin, C.T.; Tang, J.L.; Li, C.C.; Yao, M.; Tsay, W.; et al. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer 2019, 19, 617. Dodge, J.E.; Okano, M.; Dick, F.; Tsujimoto, N.; Chen, T.; Wang, S.; Ueda, Y.; Dyson, N.; Li, E. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J. Biol. Chem. 2005, 280, 17986–17991.
  16. Kuang, X.; Chi, J.; Wang, L. Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes. Hematology 2016, 21, 593–602. Gowher, H.; Jeltsch, A. Mammalian DNA methyltransferases: New discoveries and open questions. Biochem. Soc. Trans. 2018, 46, 1191–1202.
  17. Kirimura, S.; Kurata, M.; Nakagawa, Y.; Onishi, I.; Abe-Suzuki, S.; Abe, S.; Yamamoto, K.; Kitagawa, M. Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia. Pathology 2016, 48, 233–241. Jurkowska, R.Z.; Jurkowski, T.P.; Jeltsch, A. Structure and function of mammalian DNA methyltransferases. ChemBioChem Eur. J. Chem. Biol. 2011, 12, 206–222.
  18. Lyu, C.; Liu, K.; Jiang, Y.; Wang, T.; Wang, Y.; Xu, R. Integrated analysis on mRNA microarray and microRNA microarray to screen immune-related biomarkers and pathways in myelodysplastic syndrome. Hematology 2021, 26, 417–431. Klose, R.J.; Bird, A.P. Genomic DNA methylation: The mark and its mediators. Trends Biochem. Sci. 2006, 31, 89–97.
  19. Ghoshal, K.; Datta, J.; Majumder, S.; Bai, S.; Kutay, H.; Motiwala, T.; Jacob, S.T. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 2005, 25, 4727–4741. Margot, J.B.; Cardoso, M.C.; Leonhardt, H. Mammalian DNA methyltransferases show different subnuclear distributions. J. Cell. Biochem. 2001, 83, 373–379.
  20. Hollenbach, P.W.; Nguyen, A.N.; Brady, H.; Williams, M.; Ning, Y.; Richard, N.; Krushel, L.; Aukerman, S.L.; Heise, C.; MacBeth, K.J. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 2010, 5, e9001. Dukatz, M.; Adam, S.; Biswal, M.; Song, J.; Bashtrykov, P.; Jeltsch, A. Complex DNA sequence readout mechanisms of the DNMT3B DNA methyltransferase. Nucleic Acids Res. 2020, 48, 11495–11509.
  21. Dombret, H.; Seymour, J.F.; Butrym, A.; Wierzbowska, A.; Selleslag, D.; Jang, J.H.; Kumar, R.; Cavenagh, J.; Schuh, A.C.; Candoni, A.; et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015, 126, 291–299. Lin, I.G.; Han, L.; Taghva, A.; O’Brien, L.E.; Hsieh, C.L. Murine de novo methyltransferase Dnmt3a demonstrates strand asymmetry and site preference in the methylation of DNA in vitro. Mol. Cell. Biol. 2002, 22, 704–723.
  22. Fenaux, P.; Mufti, G.J.; Hellstrom-Lindberg, E.; Santini, V.; Finelli, C.; Giagounidis, A.; Schoch, R.; Gattermann, N.; Sanz, G.; List, A.; et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol. 2009, 10, 223–232. Takahashi, M.; Kamei, Y.; Ehara, T.; Yuan, X.; Suganami, T.; Takai-Igarashi, T.; Hatada, I.; Ogawa, Y. Analysis of DNA methylation change induced by Dnmt3b in mouse hepatocytes. Biochem. Biophys. Res. Commun. 2013, 434, 873–878.
  23. Zeidan, A.M.; Stahl, M.; DeVeaux, M.; Giri, S.; Huntington, S.; Podoltsev, N.; Wang, R.; Ma, X.; Davidoff, A.J.; Gore, S.D. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: Are we using realistic estimates? Blood Cancer J. 2018, 8, 55. Mortusewicz, O.; Schermelleh, L.; Walter, J.; Cardoso, M.C.; Leonhardt, H. Recruitment of DNA methyltransferase I to DNA repair sites. Proc. Natl. Acad. Sci. USA 2005, 102, 8905–8909.
  24. Zeng, Y.; Chen, T. DNA Methylation Reprogramming during Mammalian Development. Genes 2019, 10, 257. Hervouet, E.; Vallette, F.M.; Cartron, P.F. Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis. 2010, 1, e8.
  25. Dodge, J.E.; Okano, M.; Dick, F.; Tsujimoto, N.; Chen, T.; Wang, S.; Ueda, Y.; Dyson, N.; Li, E. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J. Biol. Chem. 2005, 280, 17986–17991. Hervouet, E.; Peixoto, P.; Delage-Mourroux, R.; Boyer-Guittaut, M.; Cartron, P.F. Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clin. Epigenetics 2018, 10, 17.
  26. Gowher, H.; Jeltsch, A. Mammalian DNA methyltransferases: New discoveries and open questions. Biochem. Soc. Trans. 2018, 46, 1191–1202. Khan, H.; Vale, C.; Bhagat, T.; Verma, A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin. Hematol. 2013, 50, 16–37.
  27. Jurkowska, R.Z.; Jurkowski, T.P.; Jeltsch, A. Structure and function of mammalian DNA methyltransferases. ChemBioChem Eur. J. Chem. Biol. 2011, 12, 206–222. Lopez, V.; Fernandez, A.F.; Fraga, M.F. The role of 5-hydroxymethylcytosine in development, aging and age-related diseases. Ageing Res. Rev. 2017, 37, 28–38.
  28. Klose, R.J.; Bird, A.P. Genomic DNA methylation: The mark and its mediators. Trends Biochem. Sci. 2006, 31, 89–97. Zhang, Y.; Zhou, C. Formation and biological consequences of 5-Formylcytosine in genomic DNA. DNA Repair 2019, 81, 102649.
  29. Margot, J.B.; Cardoso, M.C.; Leonhardt, H. Mammalian DNA methyltransferases show different subnuclear distributions. J. Cell. Biochem. 2001, 83, 373–379. Szulik, M.W.; Pallan, P.S.; Nocek, B.; Voehler, M.; Banerjee, S.; Brooks, S.; Joachimiak, A.; Egli, M.; Eichman, B.F.; Stone, M.P. Differential stabilities and sequence-dependent base pair opening dynamics of Watson-Crick base pairs with 5-hydroxymethylcytosine, 5-formylcytosine, or 5-carboxylcytosine. Biochemistry 2015, 54, 1294–1305.
  30. Dukatz, M.; Adam, S.; Biswal, M.; Song, J.; Bashtrykov, P.; Jeltsch, A. Complex DNA sequence readout mechanisms of the DNMT3B DNA methyltransferase. Nucleic Acids Res. 2020, 48, 11495–11509. Nimer, S.D. Myelodysplastic syndromes. Blood 2008, 111, 4841–4851.
  31. Lin, I.G.; Han, L.; Taghva, A.; O’Brien, L.E.; Hsieh, C.L. Murine de novo methyltransferase Dnmt3a demonstrates strand asymmetry and site preference in the methylation of DNA in vitro. Mol. Cell. Biol. 2002, 22, 704–723. Van Rompay, A.R.; Norda, A.; Linden, K.; Johansson, M.; Karlsson, A. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol. Pharmacol. 2001, 59, 1181–1186.
  32. Takahashi, M.; Kamei, Y.; Ehara, T.; Yuan, X.; Suganami, T.; Takai-Igarashi, T.; Hatada, I.; Ogawa, Y. Analysis of DNA methylation change induced by Dnmt3b in mouse hepatocytes. Biochem. Biophys. Res. Commun. 2013, 434, 873–878. Creusot, F.; Acs, G.; Christman, J.K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J. Biol. Chem. 1982, 257, 2041–2048.
  33. Mortusewicz, O.; Schermelleh, L.; Walter, J.; Cardoso, M.C.; Leonhardt, H. Recruitment of DNA methyltransferase I to DNA repair sites. Proc. Natl. Acad. Sci. USA 2005, 102, 8905–8909. Ghoshal, K.; Datta, J.; Majumder, S.; Bai, S.; Dong, X.; Parthun, M.; Jacob, S.T. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol. Cell. Biol. 2002, 22, 8302–8319.
  34. Hervouet, E.; Vallette, F.M.; Cartron, P.F. Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis. 2010, 1, e8. Datta, J.; Ghoshal, K.; Motiwala, T.; Jacob, S.T. Novel Insights into the Molecular Mechanism of Action of DNA Hypomethylating Agents: Role of Protein Kinase C delta in Decitabine-Induced Degradation of DNA Methyltransferase 1. Genes Cancer 2012, 3, 71–81.
  35. Hervouet, E.; Peixoto, P.; Delage-Mourroux, R.; Boyer-Guittaut, M.; Cartron, P.F. Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clin. Epigenetics 2018, 10, 17. Easwaran, H.P.; Schermelleh, L.; Leonhardt, H.; Cardoso, M.C. Replication-independent chromatin loading of Dnmt1 during G2 and M phases. EMBO Rep. 2004, 5, 1181–1186.
  36. Khan, H.; Vale, C.; Bhagat, T.; Verma, A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin. Hematol. 2013, 50, 16–37. Diesch, J.; Zwick, A.; Garz, A.K.; Palau, A.; Buschbeck, M.; Gotze, K.S. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin. Epigenetics 2016, 8, 71.
  37. Lopez, V.; Fernandez, A.F.; Fraga, M.F. The role of 5-hydroxymethylcytosine in development, aging and age-related diseases. Ageing Res. Rev. 2017, 37, 28–38. Stomper, J.; Rotondo, J.C.; Greve, G.; Lubbert, M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies. Leukemia 2021, 35, 1873–1889.
  38. Zhang, Y.; Zhou, C. Formation and biological consequences of 5-Formylcytosine in genomic DNA. DNA Repair 2019, 81, 102649.
  39. Szulik, M.W.; Pallan, P.S.; Nocek, B.; Voehler, M.; Banerjee, S.; Brooks, S.; Joachimiak, A.; Egli, M.; Eichman, B.F.; Stone, M.P. Differential stabilities and sequence-dependent base pair opening dynamics of Watson-Crick base pairs with 5-hydroxymethylcytosine, 5-formylcytosine, or 5-carboxylcytosine. Biochemistry 2015, 54, 1294–1305.
  40. Nimer, S.D. Myelodysplastic syndromes. Blood 2008, 111, 4841–4851.
  41. Van Rompay, A.R.; Norda, A.; Linden, K.; Johansson, M.; Karlsson, A. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol. Pharmacol. 2001, 59, 1181–1186.
  42. Creusot, F.; Acs, G.; Christman, J.K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J. Biol. Chem. 1982, 257, 2041–2048.
  43. Ghoshal, K.; Datta, J.; Majumder, S.; Bai, S.; Dong, X.; Parthun, M.; Jacob, S.T. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol. Cell. Biol. 2002, 22, 8302–8319.
  44. Datta, J.; Ghoshal, K.; Motiwala, T.; Jacob, S.T. Novel Insights into the Molecular Mechanism of Action of DNA Hypomethylating Agents: Role of Protein Kinase C delta in Decitabine-Induced Degradation of DNA Methyltransferase 1. Genes Cancer 2012, 3, 71–81.
  45. Easwaran, H.P.; Schermelleh, L.; Leonhardt, H.; Cardoso, M.C. Replication-independent chromatin loading of Dnmt1 during G2 and M phases. EMBO Rep. 2004, 5, 1181–1186.
  46. Diesch, J.; Zwick, A.; Garz, A.K.; Palau, A.; Buschbeck, M.; Gotze, K.S. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin. Epigenetics 2016, 8, 71.
  47. Stomper, J.; Rotondo, J.C.; Greve, G.; Lubbert, M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies. Leukemia 2021, 35, 1873–1889.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback